HSA
EGRX

Hussman Strategic Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Hussman Strategic Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-25,000
Closed -$1.01M – 279
2018
Q4 		$1.01M Hold
25,000
– – 0.24% 159
2018
Q3 		$1.73M Buy
+25,000
New +$1.9M 0.5% 90

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Hussman Strategic Advisors's EGRX Position: Q1 2019 in Review

Hussman Strategic Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2019, closing a stake of 25,000 shares — an estimated $1.01M sold.

Hussman Strategic Advisors first reported a position in EGRX in Q3 2018 and held it in 2 quarters. The position peaked at $1.73M in Q3 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q1 2019.

  • Hussman Strategic Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Hussman Strategic Advisors sold 25,000 Eagle Pharmaceuticals, Inc. shares in Q1 2019, an estimated $1.01M.
  • Hussman Strategic Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2018 and held it in 2 quarters.
  • Hussman Strategic Advisors's Eagle Pharmaceuticals, Inc. position peaked at $1.73M in Q3 2018.
  • 182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2019.

Based on Hussman Strategic Advisors's 13F filing for Q1 2019, filed 1 May 2019.